血必净联合胸腺肽α1治疗重症肺炎合并脓毒症的临床效果分析

目的：探究血必净注射液联合胸腺肽α1治疗重症肺炎合并脓毒症的临床效果。方法：本研究自2013年3月-2015年2月收集某院治疗的180例重症肺炎合并脓毒症患者的临床资料，将符合标准的70例患者随机分为观察组、对照组，2组患者的一般资料具有可比性。2组患者均给予早期积极抗感染、液体复苏、营养支持等综合治疗方案，对照组给予静脉滴注50 mL血必净注射液，观察组在对照组基础上皮下注射1.6 mg胸腺肽α1。统计分析2组患者治疗前后一般状态、血气状态、炎症因子水平、临床有效率、细菌清除率及不良反应等。结果：2组患者治疗后一般状态、血气状态、炎症因子水平均优于治疗前，2组患者治疗后体温无明显差异（P>0.05），观察组治疗后呼吸、心率、白细胞计数明显低于对照组（P<0.05），观察组治疗后pH、PaCO₂、PaO₂/FiO₂明显优于对照组（P<0.05），观察组治疗后血清白细胞介素-6（IL-6）、血清肿瘤坏死因子α（TNF-α）、血清前降钙素（PCT）、C反应蛋白（CRP）水平明显低于对照组（P<0.05），观察组患者临床有效率为85.7%，细菌清除率为82.9%，对照组临床有效率为62.9%，细菌清除率为57.1%，差异有统计学意义（P<0.05），治疗过程中并未出现严重药物相关不良反应。结论：胸腺肽α1与血必净注射液能明显改善重症肺炎合并脓毒症患者身体状态，减缓炎症进展，效果显著，同时不良反应较少，安全性较高，值得临床推广。

Clinical effects of Xuebijing injection combined with thymosin α1 against severe pneumonia with sepsis

OBJECTIVE To explore effects of Xuebijing injection combined with thymosin α1 against severe pneumonia with sepsis.METHODS Seventy patients diagnosed severe pneumonia with sepsis and met criteria were enrolled from March 2013 to February 2015, randomly divided into two groups:observation group and control group.General information of two groups were comparable.All patients received conventional treatment including fluid resuscitation, early and aggressive anti-infection and nutritional support.Patients in control group received 50 ml of Xuebijing injection, and patients in observation group additionally received subcutaneous injection of thymosin α1.General conditions, blood gas status, levels of inflammatory cytokines, clinical effective rate, bacterial clearance rate and adverse reactions were recorded.RESULTS General conditions, blood gas status, levels of inflammatory cytokines of patients after treatment were superior to those before treatment (P<0.05).Body temperatures of two groups showed no significant difference after treatment (P>0.05).Respiration, heart rate, white blood cell count of observation group were lower than those of control group (P<0.05).The pH, PaCO₂, PaO₂/FiO₂ of observation group were superior to those of control group (P<0.05).Serum levels of IL-6, TNF-α, PCT and CRP of observation group were lower than those of control group (P<0.05).Clinical effective rate and bacterial clearance rate were 85.7% and 82.9% in observation group, 62.9% and 57.1% in control group (P<0.05).Drug-related adverse reactions were not found during treatment.CONCLUSION Xuebijing injection combined with thymosin α1 can effectively improve general conditions of patients with severe pneumonia with sepsis, slow down progress of inflammation, and produce fewer adverse reactions.This combination is worthy to be promoted for its high safety and good efficacy.